Evolution Biotechnologies | 2020 June
0
archive,date,ajax_fade,page_not_loaded,,qode-title-hidden,qode-theme-ver-16.4,qode-theme-bridge,wpb-js-composer js-comp-ver-5.4.7,vc_responsive

Bedford, UK, June 8th 2020 Evolution Biotechnologies (www.evolutionbiotech.com), the UK-based company pioneering the use of biological control to benefit human health, today reports that it has received advance assurance of eligibility for the Enterprise Investment Scheme (EIS) status from the tax authorities in the UK for its next investment round. The EIS scheme provides additional tax relief for UK-based investors, and Evolution has secured EIS pre-approval for up to £3 million of investment. About Evolution Biotechnologies Evolution Biotechnologies (UK company 09473027) is working to extend the application of biological control from its proven efficacy in agriculture into biomedical markets. The company’s initial target is...